Market OverviewBiologic therapies are transforming refractory non-infectious uveitis management by targeting specific inflammatory cytokines and pathways that drive ocular inflammation unresponsive to conventional immunosuppressive therapy. Anti-TNF agents, IL-6 inhibitors, and emerging biologics targeting novel inflammatory mediators are achieving disease control in patients who previously...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek